Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) announced that, the registration of in-licensed product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization by China National Medical Products Administration (NMPA). INOmax®, the first medicinal gas product approved in China, is an inhaled nitric oxide pharmaceutical for treating term and near-term neonates (>34weeks) with hypoxic respiratory failure (HRF) associated with pulmonary hypertension (PPHN). It is indicated to improve oxygenation and reduce the need for extra-corporeal membrane oxygenation (ECMO) of patients.
Thai 
English